- Clinical science
Narcolepsy is a neurological disorder of the sleep-wake cycle characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations upon waking or falling asleep. It most commonly manifests in teens and young adults with excessive daytime sleepiness. Primary narcolepsy is either caused by orexin deficiency (type 1) or is idiopathic (type 2). Secondary narcolepsy can occur as a result of brain damage or other genetic syndromes. Diagnosis requires an established history based on questionnaires or a sleep diary as well as a polysomnogram and multiple sleep latency test or an abnormal orexin A (hypocretin-1) level in the cerebrospinal fluid (CSF). No cure has yet been found, but daytime sleepiness can be managed with CNS stimulants (e.g., modafinil) and a regimen of scheduled naps. Cataplexy, hallucinations, and sleep paralysis are treated with antidepressants or sodium oxybate.
Narcolepsy type 1
- Loss of hypothalamic neurons, which produce orexin A and orexin B (i.e., hypocretin-1 and hypocretin-2) → severe orexin deficiency
- The exact etiology is unknown, but both genetic and environmental factors seem to be implicated.
- Genetic predisposition 
- Environmental factors: e.g., streptococcal pharyngitis, exposure to H1N1 influenza antigens during vaccination (autoimmune cross-reactivity) 
Narcolepsy type 2
- No changes in orexin levels
- Cerebral damage (e.g., tumor, stroke, inflammation, vascular malformation)
- Genetic syndromes (e.g., type C and )
Excessive daytime sleepiness (EDS); : Affected individuals experience an irresistible urge to sleep and sudden, short sleep attacks (< 30 minutes), which may occur in inappropriate situations (e.g., while driving a car).
- One of the earliest manifestations of narcolepsy
- Episodes of excessive sleepiness can occur even if affected individuals have had adequate sleep.
Abnormal REM sleep
Cataplexy (60–70% of cases): sudden muscle weakness in a fully conscious person, triggered by strong emotions (affected individuals may experience buckling of the knees upon laughing.)
- Typically manifests months or even years after EDS
- The loss of muscle tone is similar to that observed during REM sleep.
- Typically manifests as partial cataplexy: isolated weakness of distinct muscle groups (e.g., neck muscles weaken and head tilts forward)
- Usually resolves within a few seconds, at most two minutes
- Sleep paralysis; (∼ 50% of cases): Complete paralysis occurs for 1–2 minutes after waking or before falling asleep; external stimuli (e.g., stirring or addressing the affected individual) can relieve paralysis.
- Cataplexy (60–70% of cases): sudden muscle weakness in a fully conscious person, triggered by strong emotions (affected individuals may experience buckling of the knees upon laughing.)
- Hypnagogic hallucinations; (∼ 50% of cases): vivid, often frightening visual or auditory hallucinations that occur as the patient falls asleep
- while waking up (less common than hypnagogic hallucinations): experienced
- Automatic behavior: During narcoleptic episodes, patients often perform routine repetitive tasks automatically without conscious awareness of their environment.
- Other: : depression, obesity, impotence or low sex drive, headaches, decreased functional performance
Hypnagogic hallucinations occur while going to sleep.
- Diagnostic criteria 
- Sleep diary
- Narcolepsy questionnaires
- Conducted in a sleep laboratory during sleep, typically over the course of two days
- PSG measures brain waves via electroencephalography (EEG), eye movements via electrooculography (EOG), and muscle activity via electromyography (EMG).
- PSG findings are characterized by EEG beta waves that appear abnormally early after falling asleep (shortened ).
- Multiple sleep latency test (MSLT)
- Measures time needed to fall asleep during daytime naps to assess excessive daytime sleepiness
- Polysomnography is made during the day; five opportunities to nap are provided
- For a conclusive MSLT, patients must have at least six hours of normal sleep as assessed by PSG prior to the test.
- Supports diagnosis if patient both:
- Falls asleep with a mean latency of ≤ 8 minutes
- Shows sleep-onset REM periods (SOREMPs) within 15 minutes after sleep onset in at least 2 out of the 5 opportunities provided
- Decreased CSF orexin A levels: supports diagnosis if ≤ 110 pg/mL or < ⅓ of mean values in healthy persons
- Additional tests
Sleep hygiene recommendations
- Take scheduled naps throughout the day to reduce the urge to sleep.
- Ensure regular sleep periods during the night.
- Avoid substances that disturb the sleep-wake cycle (e.g., alcohol, antipsychotics, opiates).
- Consultations with family and employer (e.g., people with narcolepsy require a place to sleep at their workplace)
Automobile accidents are a concern! Patients should take treatment and be symptom-free to be allowed to drive.
Excessive daytime sleepiness
- Drug of choice: modafinil (nonamphetamine CNS stimulant)
- CNS stimulants
Cataplexy, sleep paralysis, and sleep hallucinations
- SSRIs (e.g, citalopram) or SNRIs (e.g., venlafaxine)
- Nighttime sodium oxybate (highly effective for severe cataplexy)
There is no known cure for narcolepsy, but symptomatic management is possible.